| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Treatment of mice with alpha-galactosylcermide, a specific agonist for NKT cells, induces liver injury. To investigate the mechanisms of a-GalCer induced liver injury, we focused on two factors, RASAL3 and MDSC(Myeloid-derive suppressor cells).
1. RASAL3 which is a hematopoietic RasGAP protein, was found to be predominantly expressed in liver NKT cells. Analysis of RASAL3-deficient mice demonstrated that RASAL3 contributes to aggravation of liver injury by regulating NKT cell function.
2. The number of myeloid-derive suppressor cells (MDSC) was increased in the liver of a-GalCer treated mice. These MDCS were found to suppress liver injury by regulating NKT cell activation through the production of inhibitory cytokines.
|
